Welcome, Guest. Please login or register.
October 20, 2017, 10:34:01 PM

Login with username, password and session length

  • Total Members: 31667
  • Latest: Kaz86
  • Total Posts: 721005
  • Total Topics: 58484
  • Online Today: 312
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 3
Guests: 233
Total: 236


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: bevirimat (PA-457)  (Read 2361 times)

0 Members and 1 Guest are viewing this topic.

Offline postino

  • Member
  • Posts: 7
bevirimat (PA-457)
« on: December 31, 2008, 01:24:44 PM »


what is your opinion on that?

Offline leit

  • Member
  • Posts: 236
Re: bevirimat (PA-457)
« Reply #1 on: December 31, 2008, 03:37:14 PM »

Indeed, it's the first ARV drug that, in a sense, reverses the resistance issue: Lots of people have already failed it beforehand!!!  ;)

Offline Pepino2

  • Member
  • Posts: 36
  • Facial wasting need not be...Teach PMMA!
Re: bevirimat (PA-457)
« Reply #2 on: December 31, 2008, 06:11:00 PM »
I understand this post may better fit under a Credit Crunch Impacts on HIV research...please feel free to move this thread if there is any interest in this topic.

I happen to be looking through the subject of Maturation Inhibitors (bevirimat (PA-457) and came across a potentially good example of the impacts this crazy economy may be having on some junior research companies (or on all of them for that matter).

I researched the company ...Panacos Pharmaceuticals Inc. (PANC) and what strikes me is not the results of any recent breaking news with regards to Maturation Inhibitors but rather the impact of the overall economy could be having on their research and company altogether.

In a nutshell, their trial studies can be summarized (from press release that is) therein;

WATERTOWN, Mass.--(BUSINESS WIRE)--March 4, 2008--Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. In addition, it has completed a Phase 2b study (Study 203) of five treatment-experienced patient cohorts with doses ranging up to 400 mg daily and provided preliminary analysis of the combined study results. Patients who had the predictors of response and effective bevirimat target blood levels had a mean viral load reduction of 1.26 log10. The active dose range and plasma concentrations required for optimal response to bevirimat have been determined and are achievable using existing solid or liquid formulations. Clinically, bevirimat's adverse event profile was indistinguishable from placebo across all doses in the study.

"In a very short period of time we have made a number of significant discoveries with regard to bevirimat," said Dr. Alan W. Dunton, Panacos' President and CEO. "We can specifically target the patients who will respond well to bevirimat in advance. In that population, we have seen a dramatic treatment response: a greater mean viral load reduction than in any other HIV drug with a published functional monotherapy study. The favorable safety profile of bevirimat also suggests its potential utility in earlier treatment lines."

What strikes me is this;
1.  Total Market capitalization as at Dec. 31st, 2008:  $7.3M USD

Yes only $7.3M USD.  We are talking about HIV here!

2.  Dec. 10th, 2008 Press Release (http://www.panacos.com/press_detail.htm?1115284

Especially the following;

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 10, 2008--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), today provided an update on its corporate strategy. The Company is reducing its workforce, effective immediately, from 33 employees to 15. These actions are being taken to manage capital resources while Panacos pursues strategic alternatives, including the financing, partnering or sale of the Company or one of its several antiviral assets, including bevirimat (PA-457), the Company's first-in-class maturation inhibitor, which is currently in Phase 2b clinical studies in HIV-positive patients, the next-generation maturation inhibitor program (consisting of second- and third-generation compounds) and the oral fusion program (consisting of its lead compound, PA-161).

"Our talented and dedicated development team has worked so diligently on programs that continue to show great promise," stated Alan W. Dunton, MD, President and Chief Executive of Panacos. "However, we are faced with the reality that we must take drastic measures to reflect the current market environment. These actions are in line with our goal to secure partnerships or sale for our spectrum of HIV programs, including bevirimat, our second- and third-generation maturation inhibitors, as well as the oral fusion inhibitor program. Ultimately, everyone at Panacos is dedicated to ensuring HIV patients have access to these compounds, as there are limited choices for patients once their virus becomes resistant to the treatments that are currently available."

I am not advocating anything with regards to their products competitiveness in today's (and tomorrows) radically different HIV treatment alternatives, however it begs a question....

Is there a risk here that in today's economic mess some promising drugs get shelved? 

The share price closed at $0.1364 USD today.  Up 4.92%

Happy new year Everyone
PS.  I did not read their financial statements, will leave that to someone else.
« Last Edit: December 31, 2008, 06:26:40 PM by Pepino2 »


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.